AimsTo explore healthcare professionals' perceptions and experiences of take‐home naloxone initiatives in acute care settings to gain an understanding of issues facilitating or impeding dispensing.DesignSystematic literature review.Data SourcesCochrane, MEDLINE and CINAHL were searched from 15/03/2021 to 18/03/2021, with a follow‐up search performed via PubMed on 22/03/2021. The years 2011 to 2021 were included in the search.Review MethodsA systematic literature review focused on qualitative studies and quantitative survey designs. Synthesis without meta‐analysis was undertaken using a thematic analysis approach.ResultsSeven articles from the United States of America (5), Australia (1) and Canada (1) with 750 participants were included in the review. Results indicate ongoing stigma towards people who use drugs with preconceived moral concerns regarding take‐home naloxone. There was confusion regarding roles and responsibilities in take‐home naloxone dispensing and patient education. Similarly, there was a lack of clarity over logistical and financial issues.ConclusionTake‐home naloxone is a vital harm reduction initiative. However, barriers exist that prevent the optimum implementation of these initiatives.ImpactWhat is already known: Deaths due to opioid overdose are a global health concern, with take‐home naloxone emerging as a key harm reduction scheme. Globally, less than 10% of people who use drugs have access to treatment initiatives, including take‐home naloxone. An optimum point of distribution of take‐home naloxone is post‐acute hospital care. What this paper adds: There is role confusion regarding responsibility for the provision of take‐home naloxone and patient education. This is exacerbated by inconsistent provision of training and education for healthcare professionals. Logistical or financial concerns are common and moral issues are prevalent with some healthcare professionals questioning the ethics of providing take‐home naloxone. Stigma towards people who use drugs remains evident in some acute care areas which may impact the use of this intervention. Implications for practice/policy: Further primary research should examine what training and education methods are effective in improving the distribution of take‐home naloxone in acute care. Education should focus on reduction of stigma towards people who use drugs to improve the distribution of take‐home naloxone. Standardized care guidelines may ensure interventions are offered equally and take‐home naloxone ‘champions’ could drive initiatives forward, with support from harm reduction specialists. Reporting MethodThis has adhered to the PRISMA reporting guidelines for systematic reviews.Patient or Public ContributionNo patient or public contribution.

中文翻译：

---

一项系统评价，探讨医疗保健专业人员对急症护理领域带回家的纳洛酮配药的看法

目的探讨医疗保健专业人员对急症护理环境中带回家的纳洛酮举措的看法和经验，以了解促进或阻碍配药的问题。设计系统文献综述。数据来源Cochrane、MEDLINE 和 CINAHL 于 2021 年 3 月 15 日至 18 日进行搜索2021 年 3 月，并于 2021 年 3 月 22 日通过 PubMed 进行了后续检索。检索范围包括 2011 年至 2021 年。 综述方法系统文献综述侧重于定性研究和定量调查设计。使用主题分析方法进行不进行荟萃分析的综合。 结果 本综述纳入了来自美国 (5)、澳大利亚 (1) 和加拿大 (1) 的 7 篇文章，共有 750 名参与者。结果表明，对带回家的纳洛酮抱有先入为主的道德担忧的吸毒者持续受到耻辱。关于带回家的纳洛酮配药和患者教育的角色和责任存在混乱。同样，后勤和财务问题也缺乏明确性。 结论 带回家的纳洛酮是一项重要的减少危害举措。然而，存在阻碍这些举措最佳实施的障碍。影响已知： 阿片类药物过量导致的死亡是一个全球性的健康问题，带回家的纳洛酮正在成为一项关键的减害方案。 在全球范围内，只有不到 10% 的吸毒者能够获得治疗方案，包括带回家的纳洛酮。 带回家的纳洛酮的最佳分配点是急性后医院护理。 本文添加了什么： 在提供带回家的纳洛酮和患者教育的责任方面存在角色混乱。为医疗保健专业人员提供的培训和教育不一致，加剧了这种情况。 后勤或财务问题很常见，道德问题也很普遍，一些医疗保健专业人员质疑提供带回家的纳洛酮的道德问题。 在一些急症护理领域，对吸毒者的耻辱仍然很明显，这可能会影响这种干预措施的使用。 对实践/政策的影响： 进一步的初步研究应该探讨哪些培训和教育方法可以有效改善急性护理中带回家的纳洛酮的分配。 教育应侧重于减少对吸毒者的耻辱，以改善带回家的纳洛酮的分配。 标准化护理指南可以确保平等地提供干预措施，带回家的纳洛酮“冠军”可以在减少伤害专家的支持下推动举措向前发展。 报告方法本报告遵循 PRISMA 系统评价报告指南。患者或公众贡献 无患者或公众贡献。